Organization

Idience

1 clinical trial

1 abstract

Clinical trial

An Open-label, Multi-center, Phase 1b/2a Basket Trial of IDX-1197 in Patients With Homologous Recombination Repair Mutated Solid Tumors

Status: Active (not recruiting), Estimated PCD: 2023-12-31

Abstract

Co-mutation of ATM and ASXL1 and relationship to durable response of a novel PARP1/2 inhibitor, venadaparib, in patients with pancreatic cancer.

Org: Idience, Idience Inc.,